In silico molecular docking and ADME/T analysis of Quercetin compound with its evaluation of broad-spectrum therapeutic potential against particular diseases

Md Mahmudul Hasan [a], Zidan Khan [a], Mohammed Salahuddin Chowdhury [a], Md Arif Khan [b], Mohammad Ali Moni [c,e], Md Habibur Rahman [d,*]

[a] *Department of Pharmacy, International Islamic University Chittagong, Kumira, 4318, Chittagong, Bangladesh*
[b] *Dept of Biotechnology and Genetic Engineering, University of Development Alternative, Dhaka, Bangladesh*
[c] *Dept of Computer Science and Engineering, Pabna University of Science and Technology, Bangladesh*
[d] *Dept of Computer Science and Engineering, Islamic University, Kushtia, 7003, Bangladesh*
[e] *School of Health and Rehabilitation Sciences, Faculty of Health and Behavioural Sciences, The University of Queensland St Lucia, QLD 4072, Australia*

ARTICLE INFO

ABSTRACT

Progression in computational research has made it possible for the *in silico* methods to offer epochal benefits to both regulatory needs and the pharmaceutical industry to assess the safety profile. Myriad amounts of flavonoids are present in the human diet. They showed potential therapeutic effects against a wide range of illnesses. One of the most ubiquitously distributed and extensively studied flavonoids is flavonol Quercetin (Quercetin). The current study aspires to reveal Quercetin as a potent inhibitor against Tuberculosis, Malaria, Inflammatory diseases, Breast cancer, Obesity, and Alzheimer's disease in analogy to the standard drugs of each disease. A molecular docking study of Quercetin with specific proteins associated with the diseases was done using Schrodinger Maestro (v11.1) software. The QikProp module of Schrodinger Maestro was used for ADME prediction, and the admetSAR online database evaluated the toxicity of the ligand. Molecular docking results also showed higher scores than commercially available standard drugs. Moreover, ADME properties of Quercetin are delineated with no carcinogenicity and mutagenicity along with lower rat acute toxicity & acceptable oral acute toxicity level. Quercetin possessed higher scores (−9.00, −6.36, −8.53, −7.28, −7.89, −6.68 kcal/mol) as Anti-tuberculosis, Anti-malarial, Anti-inflammatory, Antineoplastic (Breast –cancer), Anti-obesity and Anti-Alzheimers drugs, respectively when compared to the standard drugs. Therefore, from the docking score, we can conclude that Quercetin can be a more potent inhibitory potential agent against selected diseases than the drugs available in the market. However, congenial clinical and empirical studies are required to explicit Quercetin as an effectual candidate drug with equitable treatment of the above-referred diseases.

1. Introduction

QUERCETIN (primarily known as Quercetin glycosides, $C_{15}H_{10}O_7$, a polyphenolic bioflavonoid that is most copious of the flavonoid molecules and widely distributed in the plant kingdom [1,2]. It was found in Avena sativa (oats), Allium cepa (Onion), Brassica spp., tea (in the form of tannins), Allium sativum (garlic), pear, and spinach in a considerable amount [3]. Quercetin is also familiar as plant pigment. Quercetin has significant importance in ethnopharmacology such as its use as an antioxidant, anticancer and neuroprotective [4]. Much predilection and attention were primarily directed recently to various flavonoids existing in fruits, vegetables, and grains, training to numerous biological activities [5]. It does employ distinctly diverse biological activities, including anti-inflammatory, antioxidant, neurological, antiviral, anticancer, cardiovascular, antimicrobial, anti-diabetic, anti-hypertensive, hepato-protective, as protective of the reproductive system, anti-obesity agent, and anti-plasmodial (anti-malarial) agent [6]. When our immune system is activated, inflammatory cells are released. These cells fight bacteria or repair tissue injury. Chronic inflammation occurs when our bodies put out inflammatory cells even when we are not sick or damaged. Many chronic disorders, such as arthritis and Alzheimer's disease, have inflammation as a symptom.

While each person's sense is unique, the inflammation usually results

---

Abbreviations

- (ADMET)   Absorption, Distribution, Metabolism, Elimination & Toxicity
- (admetSAR)   Absorption, Distribution, Metabolism, Elimination & Toxicity Structure Activity Relationship
- (CRP)   C-reactive Protein
- (TNF-alpha)   Tumour Necrosis Factor Alpha
- (IL-6)   Interleukin-6
- (HER2)   Human Epidermal Growth Factor Receptor 2
- (TB)   Tuberculosis
- (MT)   Mycobacterium Tuberculosis
- (CID)   Compound Identity Number
- (OPLS3)   Optimized Potentials for Liquid Simulations 3

- (RCSB)   Research Collaboratory for Structural Bioinformatics
- (PDB)   Protein Data Bank
- (FTO)   Fat mass and Obesity
- (BACE1)   Beta-site Amyloid Precursor Protein Cleaving Enzyme 1
- (pH)   Potential of Hydrogen
- (RMSD)   Root-Mean-Square-Deviation
- (SP glide)   Standard Precision glide
- (MM/GBSA)   Molecular Mechanics/Generalized Born Surface Area
- (COVID)   Corona Virus Diseases
- (PfENR)   Plasmodium falciparum Enoyl Acyl Carrier Protein Reductase
- (NF-kB)   Nuclear Factor Kappa B
- (DNA)   Deoxyribonucleic Acid

---

in pain because of the swelling and accumulation of tissue press upon nerve endings. This pressure causes discomfort by sending pain signals to the brain [7]. It is infeasible to envision a world without pain relief. In the sixteenth century, laudanum, opium, was used as a painkiller. Opium was the source from which morphine was first extracted in a pure form in the early nineteenth century and used to relieve pain [8]. However, for their addictive properties, they had been prohibited from taking for this purpose. Commercially available drug-like Acetaminophen, including paracetamol or Tylenol, is used to relieve pain. Chronic inflammation has been linked to a higher risk of breast cancer recurrence in some studies, while anti-inflammatory medicines such as NSAIDs have been linked to a lower risk of breast cancer development in others [9]. Following the emergence of cancer-like sickness in the human body, people all over the world became familiar with Breast cancer, a type of cancer that develops in the cells of women's breasts. When cells begin to develop out of control cancer is being created. At present, the most commonest cause of cancer death in women worldwide is due to Breast cancer and the rates are drifting about five-fold around the world [10]. After lungs cancer, it is the second leading cause of cancer death among women [11].

Breast cancer is the most demotic malignancy of women in the United States, accounting for more than 40,000 deaths each year [12]. In women with breast cancer, altered inflammatory responses are common, and researchers have associated breast cancer with an inflammatory etiology. CRP, TNF-alpha, and IL-6 levels are higher in breast cancer patients. Clinical treatments involve radiotherapy, chemotherapy with anthracycline, endocrine therapy with tamoxifen, anti-HER2-therapy with trastuzumab, and surgery. Moreover, chemotherapy for breast cancer is linked to accelerated aging and increased Alzheimer's disease [13]. Malaria is an outrageous parasitic disease caused by infection with Plasmodium protozoa transmitted by an infective female Anopheles mosquito [14]. Approximately 228 million infected malaria cases worldwide are associated with 405,000 fatalities, according to documentation by World Malaria Report 2019 statistics [15,16]. In southeast Asia, out of about 1.4 billion people living in 11 countries, 1.2 billion (85.7%) are susceptible to the risk of malaria [17–19]. It is still a significant threat in many parts of the world, with resistance spreading to almost all classes of anti-malarials [20]. The limited aider of available anti-malarial drugs strengthens the exigent need for novel antimalarial compounds [3]. In regions where both diseases are prevalent, malaria and tuberculosis coinfection are unknown. Malaria can exacerbate tuberculosis (TB) containment and increase TB patient death [20]. Tuberculosis (TB) is a contagious disease transmitted by inhaling aerosolized droplets caused by *Mycobacterium tuberculosis* [2,20]. MT has very primitive origins: it has anointed (survived) over 70, 000 years and it currently infects nearly 2 billion people worldwide [21]; with around 10.4 million new cases of TB each year, almost one-third of the world's population are carriers of the TB bacillus and are

at risk for developing the active disease [20,22]. Numerous tuberculosis foci of the breast, also known as disseminated tuberculosis mastitis, create multiple ulceration and discharge sinuses on the skin in the diffuse form of the disease, which mimics inflammatory breast cancer on mammographic results. Moreover, Patients with tuberculosis have a considerably higher risk of dementia than the general population, according to a retrospective population-based cohort study [23]. Neurodegenerative diseases are prominent causes of worldwide morbidity, disability, and decreased quality of life [24]. It is the most common disease for disability in the elder [25–27]. Alzheimer's disease, a neurodegenerative disorder, is responsible for 50–60% of dementia cases [28]. The chance of this disease increases significantly due to obesity [29]. Obesity is expected but is often a major risk factor for the growth of disparate non-communicable diseases, premature death, and significant disability [30–32]. According to a new study, inflammation in the brain is responsible for the progression of dementia and Alzheimer's disease from the existence of amyloid plaque and tau tangles to the onset of dementia and Alzheimer's disease [33].

In molecular modeling, sequence analysis platforms, and clinical training management, molecular docking has been identified as a useful technique. The discovery of new drugs relies on *in silico* tools, specifically molecular docking, to simplify the overall process since it involves several stages and workflows [34]. Docking is a computational technique that samples small molecule conformations in protein binding sites and uses scoring functions to determine which conformation best complements the protein binding site. For lead identification, molecular docking is a commonly used technique. Molecular docking, on the other hand, is an essential method in structural molecular biology and computer-assisted drug design. ligand-protein docking aims to predict the most common ligand-protein binding mode(s) [35]. Any compound's therapeutic potential can be assessed first using molecular docking, which saves time and money in drug development. For example, since Quercetin has several forms of function, the current analytical research uses a computational approach to assess its pharmacologic properties against the diseases described above [36].

2. Materials and methods

2.1. Preparation of ligand and protein

The 2D structure of Quercetin (PubChem CID: 5280343) was retrieved from PubChem online database. This compound was converted into minimized 3D structure using the LigPrep wizard of Schrödinger maestro (v11.1). With the assistance of Epik, the possible ionization state was generated at target p^H 7.0 ± 2.0 for accurate tautomer enumeration and to know the protonation state in biological status [37, 38]. Completing stereoisomers at most 32 per ligand was generated by retaining specified chiralities. The force field was set to OPLS3 [39]. The

target protein used for molecular docking were downloaded from RCSB Protein Data Bank [40,41] following mycolic acid cyclopropane synthase (PDB id: 1KPI) [34] for anti-tuberculosis activity, plasmepsin II (PDB id: 1SME) for antimalarial activity, cyclooxygenase-1 (PDB id: 2OYE) [35] for an anti-inflammatory response, human estrogen receptor alpha (PDB id: 3ERT) [36] for antineoplastic (breast cancer) activity, fat mass and obesity-associated (FTO) protein (PDB id: 3LFM) [45] for gastric and pancreatic lipase inhibition activity, BACE1 (PDB id: 4IVT) [46] against Alzheimer's disease. Mycolic acid cyclopropane synthase (PDB id: 1KPI) is the drug target for tuberculosis. The mechanism of action relies on the inhibition of mycolic acid cyclopropane synthesis [34]. Plasmepsin II (PDB id: 1SME) is a key enzyme in the life cycle of the Plasmodium parasites responsible for malaria, a disease that afflicts more than 300 million individuals annually.

Since plasmepsin II inhibition leads to starvation of the parasite, it has been acknowledged as an important target for developing antimalarials [42–44]. Cyclooxygenase-1 (PDB id: 2OYE) targets many analgesic drugs to reduce pain. Blocking cyclooxygenase-1 synthesis subsequently prevents prostaglandin formation and reduces the pain [35]. Human estrogen receptor alpha (PDB id: 3ERT) is an important drug target for breast cancer. The drugs competitively inhibit estrogen binding to its receptor, which is critical for its activity in breast cancer cells [36]. Fat mass and obesity-associated (FTO) protein (PDB id: 3LFM) is responsible for an obesity-related complication. Thereby, FTO is an important target for a drug to exert an anti-obesity effect [45]. BACE1 (PDB id: 4IVT) is a prime therapeutic target for lowering cerebral A/beta concentrations in Alzheimer's disease, and clinical development of BACE1 inhibitors is intensely pursued [46].

The protein preparation wizard in Schrödinger Maestro (v11.1) was used to prepare the 3D structure of the protein. In this management, bond orders were assigned, CCD database was used, hydrogens were added, zero-order bonds to metal and disulfide bonds were created, selenomethionines were converted into methionines, water molecules were eliminated beyond 5°A from het groups, and het state was left in default pH (7.0±2.0) using Epik. Finally, restrained minimization was performed under the OPLS3 force field, which converges heavy atoms to RMSD 0.30 Å.

2.2. Identification of active site of the receptor

An active site is a specific place on the surface of the receptor where the compounds tend to bind and causes conformational changes to induce a pharmacological action [47]. The active site determination is an integral part of docking simulation because it specifies the binding site of a ligand on the receptor. The target protein's active site was selected using the PockDrug server for druggability assessment [48].

2.3. Receptor grid generation

Here the van der Waals radius scaling factor is 1, and the partial charge cutoff is 0.25, default parameters. Also, the bounding box was set, which can cover the whole target site for docking simulation.

2.4. Molecular Docking Simulation study

After the pre-requisite steps were finished, the docking simulation was carried out in the SP glide of Schrodinger maestro (v11.1) [49], considering penalties employed to non-cis/trans amide bonds. Here, the van der Waals scaling factor was set to 0.80 and the partial charge cutoff was 0.15. Energy minimized posture was employed to determine the definitive score, expressed as glide score. The score for each activity for the compound and the standard drugs was recorded.

2.5. ADMET analysis

ADME properties depict the compound accessibility throughout the body, determined by Lipinski's rule of five [50]. The standard parameter for this rule is given below:

1) Molecular weight (acceptable range:≤ 500)
2) Hydrogen bond donor (acceptable range: ≤ 5)
3) Hydrogen bond acceptor (acceptable range: ≤ 10)
4) High lipophilicity (expressed as LogP, acceptable range: ≤ 5)
5) Molar refractivity (acceptable range: 40–130)

The QikProp module of Schrödinger maestro (v11.1) was used to determine Quercetin's ADME (Absorption Distribution Metabolism Excretion) property. In addition, the toxicity profile was evaluated using admetSAR online server-based database [51]. The block diagram of the proposed work is shown in Fig. 1.

3. Results

The two-dimensional (2D) structure of the Quercetin compound is shown in Fig. 2. This study evaluated the docking simulation of Quercetin (Fig. 1) for five distinct proteins. The regarding scores for docking simulation are shown in Table 1. This compound showed promising results for selective activity compared to their respective standard drugs. The 2D and 3D representations of the interaction between the compound and protein have shown in Fig. 3. In the 2D structure of Fig. 3, green color represents hydrogen bond, and other colors include light green (van der Waals bond), blue (pi-sigma bond), yellow (pi-sulfur bond), purple (amide-pi stacked bond), light purple (pi-alkyl bond) has also shown with the atomic distances. Table 2 indicated the binding interaction (Hydrogen and hydrophobic) between Quercetin and the receptors.

3.1. ADME/T analysis

ADME property evaluates the ability of a chemical agent to act like a drug. The pharmacokinetic profile of quercetin has shown in Table 3, which depicts that it has not violated any of the criteria for the Lipinski rule and it has no mutagenic and carcinogenic properties.

4. Discussion

Quercetin is a well-known flavonoid; the key compound analyzed in this study. Analysis of ligand binding interaction by molecular docking is a well-known method of drug discovery worldwide. The results obtained from this study would help understand the inhibitory mode and rapidly and accurately predict the activities of new inhibitors based on docking scores [52]. Molecular docking provides information about the relative orientation of a ligand molecule when it is bound to a protein [53]. The discovery of novel compounds with more potency and selectivity and understanding the pharmacological activity of natural compounds at therapeutic conditions can achieve from the information resulting from in silico molecular docking study. Recent docking studies showed that Quercetin also acts as a potential treatment for COVID-19-induced acute kidney injury by inhibition of inflammatory, cell apoptosis-related signaling pathways [54–57] and as an antimalarial by inhibition of Plasmodium falciparum Enoyl Acyl Carrier Protein Reductase (PfENR) [58]. Another in silico study revealed its anti-inflammatory and anticancer activity where Quercetin effect the NF-kB pathway and docking score was −9.7 & −9.5 kcal/mol, respectively [59]. We have carried out molecular docking and ADME/T investigation to analyze Quercetin's mechanism of action against breast cancer, Alzheimer's disease, tuberculosis, obesity, and malaria. Previous studies suggested that the higher the docking score, the higher the efficacy of the novel compound against the particular disease [60].

From the perspective of our study, it has been revealed that Quercetin possesses higher docking scores (−9.00, −6.36, −8.53, −7.28, −7.89 and −6.68 kcal/mol as Anti-tuberculosis, Anti-malarial, Anti-

Fig. 1. In silico molecular docking and ADME/T analysis of Quercetin compound with its evaluation of broad-spectrum therapeutic potential against Tuberculosis, Malaria, Inflammatory diseases, Breast cancer, Obesity, and Alzheimer's disease.

Fig. 2. Two-dimensional Structure of Quercetin compound.

inflammatory, Antineoplastic especially agents against breast cancer, Anti-obesity and Anti-Alzheimer's drug respectively) against selected diseases when compared to the available standard drugs (-6.89, -6.04, -6.60; -4.18, -5.54, -4.18; -6.02, -5.07, -4.72; -4.81, -5.49, -10.83; - 3.47, -5.73, -5.41 and -4.56, -4.30, -4.77 kcal/mol for specifically Thaicetazone, Pyrazinamide, Isoniazid; Primaquine, Tafenoquine, Chloroquine; Aspirin, Ibuprofen, Naproxen; Tamoxifen, Toremifene, Raloxifene; Orlistat, Cetilistat, Lorcaserin; Galantamine, Donepezil, and Rivastigmine respectively) in the market. Thereupon, MM-GBSA analysis reveals the stronger binding of the ligands to the receptors. The binding energy (-35.37, -41.73, -19.46, -39.03, -49.51, -45.38 kcal/mol) of Quercetin and binding energy (-30.53,

-11.1, -10.98; -20.41, -47.00, -35.12; -30.90, $+3.03$, $+5.05$; -40.62, -51.69, -70.34; -18.22, -46.616, -29.53; -28.02, -31.06, -33.65 kcal/mol) of standard drugs (Thaicetazone, Pyrazinamide, Isoniazid; Primaquine, Tafenoquine, Chloroquine; Aspirin, Ibuprofen, Naproxen; Tamoxifen, Toremifene, Raloxifene; Orlistat, Cetilistat, Lorcaserin; Galantamine, Donepezil, and Rivastigmine respectively) to the selected disease-specific receptor proteins(1KPI, 1SME, 2OYE, 3ERT,3LFM & 4IVT) was yielded after MMGBSA analysis. We can assume from the above information that against tuberculosis (1KPI), malaria (1SME), obesity (2OYE), and Alzheimer's disease(3ERT), Quercetin possesses a greater score of docking as well as MM/GBSA than the standard drugs. On the other hand, In the case of Inflammation (pain)(3LFM) and breast cancer(4IVT), Quercetin possesses a greater docking score but lower MMGBSA compared to standard drugs. Overall, it can be stated from the analogy of both the scores that Quercetin can be a highly potent agent against tuberculosis, malaria, obesity, and Alzheimer's diseases and is also slightly effective against Inflammation (pain) and breast cancer.

Organic compounds can link to proteins via creating chemical bonds and non-covalent interactions between the ligand and the protein [61]. Hydrogen bond interaction and hydrophobic interaction are important considerations in evaluating binding affinity and the effectiveness of a new drug molecule to gain suitable pharmacologic properties. H-bonds play a critical role in drug-receptor interactions and the structural integrity of numerous biological components, including proteins and DNA [62]. Hydrogen bonds (H-bonds) are relatively common between ligand and protein [61]. By enabling chemical interactions, H- bonds enhance various biological functions [63]. The bond is assumed to be hydrogen if a valid hydrogen bond acceptor–donor pair is within the correct distance. The stronger the hydrogen bond, the closer it gets to perfect geometry [64]. The ligand's binding causes direct interaction with the protein to develop and the release of water molecules.

Table 1

Comparison of the Molecular Docking binding energies between Quercetin and other Standard drugs.

| Activity	Quercetin(kcal/mol)	MMGBSA	Standard drug(kcal/mol)	MMGBSA	Standard drug(kcal/mol)	MMGBSA	Standard drug(kcal/mol)	MMGBSA
Anti-tuberculosis	-9.00	-35.37	-6.89 (Thiacetazone)	-30.53	-6.04 (Pyrazinamide)	-11.1	-6.60 (Isoniazid)	-10.98
Anti-malaria	-6.36	-41.73	-4.18 (Primaquine)	-20.41	-5.54 (Tafenoquine)	-47.00	-4.18 (Chloroquine)	-35.12
Anti-inflammatory	-8.52	-19.46	-6.02 (Aspirin)	-30.90	-5.07 (Ibuprofen)	+3.03	-4.72 (Naproxen)	+5.05
Antineoplastic (breast cancer)	-7.28	-39.03	-4.81 (Tamoxifen)	-40.62	-5.49 (Toremifene)	-51.69	-10.83 (Raloxifene)	-70.34
Anti-obesity	-7.89	-49.51	-3.47 (Orlistat)	-18.22	-5.73 (Cetilistat)	-46.616	-6.41 (Lorcaserin)	-29.53
Anti-alzheimer's Disease	-6.68	-45.38	-4.56 (Galantamine)	-28.02	-4.30 (Donepezil)	-31.06	-4.77 (Rivastigmine)	-33.65

Fig. 3. Molecular Docking Simulation analysis. (a) Interaction with mycolic acid cyclopropane synthase (PDB id: 1KPI), (b) Interaction with plasmepsin II (PDB id: 1SME), (c) Interaction with cyclooxygenase-1 (PDB id: 2OYE), (d) Interaction with human estrogen receptor alpha (PDB id: 3ERT), (e) Interaction with fat mass and obesity associated (FTO) protein (PDB id: 3LFM), (f) Interaction with BACE1 (PDB id: 4IVT).

Both of these contributions are advantageous to the binding [61]. The mean donor-acceptor distances in protein secondary structure elements and those between bases in Watson-Crick pairing are close to 3.0–3.5 [65]. The majority of h-bonds in proteins are moderate. Strong h-bonds require moieties or conditions that are rare within proteins. The hydrogen atoms in moderate h-bonds often do not lie on the straight line connecting the donor to the acceptor, so donor-acceptor distance slightly underestimates the length of the h-bond [65]. In the case of Quercetin and the target proteins, the bond distance is like most of average 3.0 and in between 3.5 and 4.0, which is good enough in contrast to the available standard drugs interaction value. Hydrophobic interactions are formed when non-polar amino acid side chains of the protein and lipophilic groups on the ligand are in close contact. Hydrophobic interactions have been demonstrated to contribute significantly to the binding affinity of ligands with substantial lipophilic groups [61]. Hydrophobicity impacts a variety of biological processes, including biological molecule transport, distribution, and metabolism;

molecular recognition; and protein folding. It is vital to have a parameter that defines the behavior of solutes into polar and non-polar phases to forecast the transport and action of medications, pesticides, and xenobiotics. The more the hydrophobic interactions distance, the more the bioavailability of drug molecules [66]. Based on less bond distance (Å) or energy value of Quercetin in comparison to the standard drug in case of hydrogen bond interactions and more distance value for hydrophobic interaction with the receptor's active site suggests that Quercetin has a stronger binding affinity towards most of the protein molecules as well as a suitable bioavailability property. Future critical analysis of the binding affinity is needed for a better assumption. Pharmacokinetics and toxicological studies are vital parameters in drug discovery [66]. From the ADME/T analysis of Quercetin, according to Lipinski rule - molecular mass less than 500 Da (302.24g/mol); The molecular weight of a drug is crucial because it allows it to be absorbed by the body at the right rate and amount. It is possible to spray a liquid onto small drug cores, forming a membrane that the drug must pass through before reaching

Table 2
Binding interaction (hydrogen and hydrophobic) between quercetin and the receptors.

Proteins (PDB ID)	Ligands	Hydrogen bond interactions		Hydrophobic interactions	
		Amino acid residue	Distance (Å)	Amino acid residue	Distance (Å)
1KPI	Quercetin	TYR-41	3.07	PHE-215	6.09
		HIS-149	4.92	ILE-184	5.50
		GLY-145	3.73	ILE-210	6.45
		THR-293	4.22		
1KPI	Thiacetazone	GLU-148	4.55	ILE-184	6.62
		GLY-145	3.55	LEU-220	5.01
		TYR-41	4.30	PHE-215	5.15
		TYR-24	6.54		
1SME	Quercetin	TYR-192	6.00	TYR-77	6.37
		THR-217	3.73	LEU-131	5.57
		GLY-216	3.19		
		LEU-131	3.40		
1SME	Primaquine	ASP-34	4.34	VAL-78	5.50
				ASP-214	4.53
				ASP-34	5.04
				GLY-216	4.10
				TYR-77	3.39
2OYE	Quercetin	MET-522	3.53	TYR-385	2.39
		SER-530	3.88	GLY-526	4.57
		ASP-351	4.44	ALA-527	3.61
		GLU-353	5.04	ILE-523	5.37
				VAL-349	5.89
				LEU-352	4.92
				THR-347	4.85
				LEU-346	5.97
2OYE	Aspirin			TYR-385	7.81
				GLY-526	4.78
				ALA-527	4.20
3ERT	Quercetin	ARG-394	3.68	LEU-525	5.50
		ALA-227	5.45	ALA-350	4.70
				LEU-391	6.65
		TYR-106	5.81	LEU-384	6.03
		GLU-234	3.56	LEU-387	5.59
				VAL-228	4.90
				LEU-109	5.64
3ERT	Tamoxifen	LEU-536	4.81	GLU-380	6.04
				PRO-535	4.85
				LEU-536	5.08
				LEU-354	6.89
				LEU-525	4.48
3LFM	Quercetin	TYR-198	5.50	HIS-231	4.84
		ASP-228	4.59	TYR-108	5.44
		ASP-32	4.12	ILE-126	5.80
		ILE-126	3.87	SER-35	4.24
				TYR-198	6.52
3LMF	Orlistat	SER-229	4.16	TYR-214	4.35
				TYR-108	5.23
				TYR-106	6.53
				SER-229	3.66
				TRP-230	6.18
				ILE-85	4.76
4IVT	Quercetin	ILE-126	3.87	ILE-126	5.80
		TYR-198	5.50	TYR-198	6.52
		ASP-228	4.59	SER-35	4.24
		ASP-32	4.12		
4IVT	Galantamine	ARG-235	4.16	ASP-228	5.08
		THR-72	4.16	ASP-32	4.77
				GLY-34	3.83
				PRO-70	4.26
				TYR-71	5.06
				GLN-71	4.46
				VAL-332	7.92

Abbreviation: TYR- Tyrosine, HIS-Histidine, GLY-Glycine, ARG-Arginine, ASP-Aspartic Acid, THR- Threonine, SER-Serine, ILE-Iso-leucine, LEU- Leucine, GLU-Glutamic Acid, ALA-Alanine, MET-Methionine, GLN-Glutamine, VAL- Valine, PRO-Proline, TRP-Tryptophan, PHE-Phenylalanine.

Table 3
Ligand properties of QUERCETIN.

Molecular weight	302.24 g/mol
Hydrogen bond donor	5
Hydrogen bond acceptor	7
High lipophilicity (log P)	1.23
Molar refractivity	78.03
Mutagenicity	Non-mutagenic
Carcinogenicity	Non-carcinogenic
Acute oral toxicity	II
Rat acute toxicity	3.0200

the body.

On the other hand, hydrogen bond donor is 5, which is compatible, and also hydrogen bond receptor is less than 10 (particularly 7), which indicated good binding strength. Moreover, high lipophilicity (defined as partition co-efficient denoted as logP) is less than five or between (1.23), which indicates better absorption (Lipophilicity and molecular weight are frequently increased during drug development to improve the affinity and selectivity of the therapeutic candidate, and molar refractivity is between 40 and 130 (78.3) [67]. A drug-like molecule with a logarithm of the partition coefficient (logP) ranging from −0.4 to 5.6, a molecular weight of 160–480 g/mol, a molar refractivity of 40–130, which is proportional to the molecule's volume and molecular weight, and 20–70 atoms [68]. Thus, Quercetin satisfied all the parameters of Lipinski's five rules, including the absorption analysis, distribution, metabolism, and excretion, and exhibited good oral bioavailability. Furthermore, the toxicity analysis revealed that the compound is safe as it exhibited no mutagenic or carcinogenic properties. Also, based on the acute oral toxicity level (II) and the rat acute toxicity value is (3.020) in ADME/T analysis, the toxicity level value is within the acceptable limit in the perspective of a computer simulation study. Nevertheless, clinical investigation is needed to evaluate overall toxicity. After all, the efficacy and safety profile are quite reasonable compared to referenced drugs.

5. Conclusion

In this study, molecular docking was applied to explore the binding mechanism and correlate its docking score with the activity of the Quercetin compound. It has displayed good docking scores in comparison to the standard drugs. Quercetin and its derivatives have been studied for their pharmacological properties in recent years. We have assessed some pharmacological properties, including antineoplastic (Breast Cancer), anti-obesity, anti-inflammatory, anti-Alzheimer's disease, anti-malarial, and anti-tuberculosis. The results of our present study can be useful for the design and development of novel compounds having better inhibitory activity against several diseases. Quercetin exhibited an acceptable drug-like property with no carcinogenicity or mutagenicity. However, Quercetin and its derivatives are versatile molecules. So, this potential drug candidate can further be validated in wet lab studies for its proper function in human health with a safety profile and extensive drug interactional study should be done.

Credit author statement

Md.Mahmudul Hasan: Conception and design, or analysis and interpretation of the data, Writing – original draft, Writing – review & editing. Zidan Khan: Conception and design, or analysis and interpretation of the data, Writing – original draft, Writing – review & editing. Mohammed Salahuddin Chowdhury: Writing– original draft, Writing –

review & editing. Md Arif Khan: Writing – review & editing, Critical Revision and comments. Mohammad Ali Moni: Writing – review & editing. Md Habibur Rahman: Writing – original draft, Writing – review & editing and Supervision.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgment

We would like to thank the team members of the Bioinformatics Lab headed by Dr. Md. Habibur Rahman who helped us and provided valuable insight into the research.

References

[1] Kelly GS. Quercetin. monograph. Alternative Med Rev 2011;16(1):172–94.
[2] Jnawali HN, Jeon D, Jeong M-C, Lee E, Jin B, Ryoo S, Yoo J, Jung ID, Lee SJ, Park Y-M, et al. Antituberculosis activity of a naturally occurring flavonoid, isorhamnetin. J Nat Prod 2016;79(4):961–9.
[3] Ganesh D, Fuehrer H-P, Starzengrüber P, Swoboda P, Khan WA, Reismann JA, Mueller MS, Chiba P, Noedl H. Antiplasmodial activity of flavonol quercetin and its analogues in plasmodium falciparum: evidence from clinical isolates in Bangladesh and standardized parasite clones. Parasitol Res 2012;110(6):2289–95.
[4] Maalik A, Khan FA, Mumtaz A, Mehmood A, Azhar S, Atif M, Karim S, Altaf Y, Tariq I. Pharmacological applications of quercetin and its derivatives: a short review. Trop J Pharmaceut Res 2014;13(9):1561–6.
[5] Abu-Lafi S, Akkawi M, Al-Rimawi F, Abu-Remeleh Q, Lutgen P. Morin, quercetin, catechin and quercitrin as novel natural antimalarial candidates. 2020.
[6] Xiao X, Shi D, Liu L, Wang J, Xie X, Kang T, Deng W. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of p300 signaling. PLoS One 2011;6(8):e22934.
[7] Parameswari P, Devika R. In silico molecular docking studies of quercetin compound against anti-inflammatory and anticancer proteins. Res J Pharm Technol 2019;12(11):5305–9.
[8] Bretelle-Establet F. Frank dikötter, lars laamann, zhou xun, narcotic culture: a history of drugs in China. Hong Kong, Hong Kong university press, 2004. China Perspect 2005;2005(62):319.
[9] Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci Unit States Am 2003;100(7):3983–8.
[10] Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001; 2(3):133–40.
[11] DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics. CA A Cancer J Clin 2014;64(1):52–62. 2013.
[12] Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci Unit States Am 2003;100(7):3983–8.
[13] Ewertz M, Jensen AB. Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol 2011;50(2):187–93.
[14] Julien J-P, Wardemann H. Antibodies against plasmodium falciparum malaria at the molecular level. Nat Rev Immunol 2019;19(12):761–75.
[15] Ye Y, Andrada A. Estimating malaria incidence through modeling is a good academic exercise, but how practical is it in high-burden settings? Am J Trop Med Hyg 2020;102(4):701.
[16] Cibulskis RE, Alonso P, Aponte J, Aregawi M, Barrette A, Bergeron L, Fergus CA, Knox T, Lynch M, Patouillard E, et al. Malaria: global progress 2000–2015 and future challenges. Infectious Diseases Poverty 2016;5(1):1–8.
[17] Rudrapal M, Chetia D. Plant flavonoids as potential source of future antimalarial leads. Sys Rev Pharm 2017;8(1):13.
[18] Barnes KI. Antimalarial drugs and the control and elimination of malaria. 2011. p. 1–17.
[19] Dash A, Valecha N, Anvikar A, Kumar A. Malaria in India: challenges and opportunities. J Biosci 2008;33(4):583–92.
[20] Barberis I, Bragazzi N, Galluzzo L, Martini M. The history of tuberculosis: from the first historical records to the isolation of koch's bacillus. J Preventive Med Hygiene 2017;58(1). E9.
[21] Ribón W. Tuberculosis: expanding knowledge. BoD–Books on Demand; 2015.
[22] Sabiiti W. Beyond the numbers: interpreting who's global tuberculosis report 2016 to inform tb policy and practice in the east african community. EA Health Res J 2017;1(1):2–7.
[23] Peng Y-H, Chen C-Y, Su C-H, Muo C-H, Chen K-F, Liao W-C, Kao C-H. Increased risk of dementia among patients with pulmonary tuberculosis: a retrospective population-based cohort study. Am J Alzheimer's Dis Other Dementias 2015;30(6): 629–34.
[24] Rahman MH, Rana HK, Peng S, Kibria MG, Islam MZ, Mahmud SH, Moni MA. Bioinformatics and system biology approaches to identify pathophysiological impact of covid-19 to the progression and severity of neurological diseases. Comput Biol Med 2021:104859.
[25] Rahman MH, Rana HK, Peng S, Hu X, Chen C, Quinn JM, Moni MA. Bioinformatics and machine learning methodologies to identify the effects of central nervous system disorders on glioblastoma progression. Brief Bioinform; 2021bbaa365.
[26] Rahman MH, Peng S, Hu X, Chen C, Uddin S, Quinn JM, Moni MA. Bioinformatics methodologies to identify interactions between type 2 diabetes and neurological comorbidities. IEEE Access 2019;7. 183 948–183 970.
[27] Rahman MH, Peng S, Chen C, Moni MA, et al. Genetic effect of type 2 diabetes to the progression of neurological diseases. BioRxiv; 2018. p. 480400.
[28] Rahman MH, Sarkar2Ψ B, Islam MS, Abdullah MI. Discovering biomarkers and pathways shared by alzheimer's disease and Parkinson's disease to identify novel therapeutic targets. Int J Eng Res Technol 2020;6.
[29] Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol 2019;15(5):288–98.
[30] Research GV. Drug discovery informatics market size, share & trends analysis report by mode (in-house, outsourced), by workflow (discovery, development), by services (sequence analysis platforms, docking), and segment forecasts, 2021 - 2028," Report. 2021 [Online]. Available: https://www.grandviewresearch.com/industry-analysis/drug-discovery-informatics-market.
[31] Rahman MH, Peng S, Hu X, Chen C, Rahman MR, Uddin S, Quinn JM, Moni MA. A networkbased bioinformatics approach to identify molecular biomarkers for type 2 diabetes that are linked to the progression of neurological diseases. Int J Environ Res Publ Health 2020;17(3):1035.
[32] Podder NK, Rana HK, Azam MS, Rana MS, Akhtar MR, Rahman MR, Rahman MH, Moni MA. A system biological approach to investigate the genetic profiling and comorbidities of type 2 diabetes. Gene Reports 2020;21:100830.
[33] Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of alzheimers disease: a review of progress. J Neurol Neurosurg Psychiatr 1999;66(2): 137–47.
[34] Huang C-c, Smith CV, Glickman MS, Jacobs WR, Sacchettini JC. Crystal structures of mycolic acid cyclopropane synthases from mycobacterium tuberculosis. J Biol Chem 2002;277(13):11 559–11 569.
[35] Harman CA, Turman MV, Kozak KR, Marnett LJ, Smith WL, Garavito RM. Structural basis of enantioselective inhibition of cyclooxygenase-1 by s-?-substituted indomethacin ethanolamides. J Biol Chem 2007;282(38). 28 096–28 105.
[36] Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95(7):927–37.
[37] Hussein HA, Borrel A, Geneix C, Petitjean M, Regad L, Camproux AC. PockDrug-Server: a new web server for predicting pocket druggability on holo and apo proteins. Nucleic Acids Res 2015;43(W1):W436–42.
[38] Mahbub NI, Hasan M, Rahman MH, Naznin F, Islam MZ, Moni MA. Identifying molecular signatures and pathways shared between Alzheimer's and Huntington's disorders: a bioinformatics and systems biology approach. Informatics Med Unlocked 2022 Feb 15.
[39] Harder E, Damm W, Maple J, Wu C, Reboul M, Xiang JY, Wang L, Lupyan D, Dahlgren MK, Knight JL. Opls3: a force field providing broad coverage of drug-like small molecules and proteins. J Chem Theor Comput 2016;12(1):281–96.
[40] Rose PW, Prli A, Altunkaya A, Bi C, Bradley AR, Christie CH, Costanzo LD, Duarte JM, Dutta S, Feng Z. The rcsb protein data bank: integrative view of protein, gene and 3d structural information. Nucleic acids research; 2016gkw1000.
[41] Mahmud SH, Chen W, Liu Y, Awal MA, Ahmed K, Rahman MH, et al. Predtis: prediction of drug–target interactions based on multiple feature information using gradient boosting framework with data balancing and feature selection techniques. Briefings Bioinf 2021;22(5).
[42] Silva A, Lee A, Gulnik S, Maier P, Collins J, Bhat T, Collins P, Cachau R, Luker K, Gluzman I. Structure and inhibition of plasmepsin ii, a hemoglobin-degrading enzyme from plasmodium falciparum. Proc Natl Acad Sci Unit States Am 1996;93 (19). 10 034–10 039.
[43] Islam AH, Rahman MH, Bristy SA, Andalib KS, Khan U, Awal MA, Hossain MS, Moni MA. Identification of molecular signatures and pathways common to blood cells and brain tissue based RNA-Seq datasets of bipolar disorder: insights from comprehensive bioinformatics approach. Informatics Med Unlocked 2022 Feb 15: 100881.
[44] Bristy SA, Islam AH, Andalib KS, Khan U, Awal MA, Rahman MH. Determination of molecular signatures and pathways common to brain tissues of autism spectrum disorder: insights from comprehensive bioinformatics approach. Informatics Med Unlocked 2022 Feb 8:100871.
[45] Han Z, Niu T, Chang J, Lei X, Zhao M, Wang Q, Cheng W, Wang J, Feng Y, Chai J. Crystal structure of the fto protein reveals basis for its substrate specificity. Nature 2010;464(7292):1205–9.
[46] Zou Y, Li L, Chen W, Chen T, Ma L, Wang X, Xiong B, Xu Y, Shen J. Virtual screening and structure-based discovery of indole acylguanidines as potent ?-secretase (bace1) inhibitors. Molecules 2013;18(5):5706–22.
[47] Bongrand P. Ligand-receptor interactions. Rep Prog Phys 1999;62(6):921.
[48] Hussein HA, Borrel A, Geneix C, Petitjean M, Regad L, Camproux A-C. Pockdrug-server: a new web server for predicting pocket druggability on holo and apo proteins. Nucleic Acids Res 2015;43(W1):W436–42.
[49] Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK. Glide: a new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy. J Med Chem 2004;47 (7):1739–49.
[50] Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 2004;1(4):337–41.

[51] Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, Lee PW, Tang Y. admetsar: a comprehensive source and free tool for assessment of chemical admet properties. 2012.

[52] Muthukala B, Sivakumari K, Ashok K. In silico docking of quercetin compound against the hela cell line proteins. Int J Curr Pharmaceut Res 2015;7(1):13–6.

[53] Taylor RD, Jewsbury PJ, Essex JW. A review of protein-small molecule docking methods. J Comput Aided Mol Des 2002;16(3):151–66.

[54] Gu Y-Y, Zhang M, Cen H, Wu Y-F, Lu Z, Lu F, Liu X-S, Lan H-Y. Quercetin as a potential treatment for covid-19-induced acute kidney injury: based on network pharmacology and molecular docking study. PLoS One 2021;16(1):e0245209.

[55] Islam MK, Rahman MH, Islam MR, Islam MZ, Mamun MM, Azad AK, Moni MA. Network based systems biology approach to identify diseasome and comorbidity associations of Systemic Sclerosis with cancers. Heliyon 2022 Feb 8:e08892.

[56] Hasan MI, Rahman MH, Islam MB, Islam MZ, Hossain MA, Moni MA. Systems biology and bioinformatics approach to identify blood based signatures molecules and drug targets of patient with covid-19," Informatics in Medicine Unlocked. 2021. p. 100840.

[57] Mahmud SH, Al-Mustanjid M, Akter F, Rahman MS, Ahmed K, Rahman MH, et al. Bioinformatics and system biology approach to identify the influences of sars-cov-2 infections to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease patients. Briefings Bioinf 2021;22(5).

[58] Malau ND, Azzahra SF. Molecular docking studies of potential quercetin 3, 4'-dimethyl ether 7-alphalarabinofuranosyl-(1-6)-glucoside as inhibitor antimalaria. J Phys Conf 2020;1428(1):12057. IOP Publishing.

[59] Parameswari P, Devika R. In silico molecular docking studies of quercetin compound against anti-inflammatory and anticancer proteins. Res J Pharm Technol 2019;12(11):5305–9.

[60] Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci 2019;20(18):4331.

[61] Grabowski SJ. Intramolecular hydrogen bond energy and its decomposition interactions. Crystals 2021;11(1):5.

[62] Abelian A, Dybek M, Wallach J, Gaye B, Adejare A. Pharmaceutical chemistry. Elsevier; 2021. p. 105–28.

[63] Chen D, Oezguen N, Urvil P, Ferguson C, Dann SM, Savidge TC. Sci Adv 2016;2(3): e1501240.

[64] Lennarz WJ, Lane MD. Encyclopedia of biological chemistry. Academic Press; 2013.

[65] Jeffrey GA, Jeffrey GA. An introduction to hydrogen bonding, 12. New York: Oxford university press; 1997.

[66] Andrade E, Bento A, Cavalli J, Oliveira S, Schwanke R, Siqueira J, Freitas C, Marcon R, Calixto J. Nonclinical studies in the process of new drug development-part ii: good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Braz J Med Biol Res 2016;49.

[67] Chen X, Li H, Tian L, Li Q, Luo J, Zhang Y. Analysis of the physicochemical properties of acaricides based on lipinski's rule of five. J Comput Biol 2020;27(9): 1397–406.

[68] Vastag G, Apostolov S, Matijević B. Prediction of lipophilicity and pharmacokinetics of chloroacetamides by chemometric approach. Iran J Pharm Res (IJPR): Int J Phys Res 2018;17(1):100.